Results for tag: "Idhifa"

The Idhifa market is a subset of the larger leukemia drug market, focusing on drugs used to treat acute myeloid leukemia (AML). Idhifa is a brand name for the drug enasidenib, which is used to treat AML in adults who have a specific genetic mutation. Idhifa is the only drug approved by the US Food and Drug Administration (FDA) for this indication. Idhifa is a targeted therapy, meaning it is designed to target specific genetic mutations in cancer cells. It works by blocking the activity of a protein called isocitrate dehydrogenase 2 (IDH2), which is involved in the growth and spread of cancer cells. The Idhifa market is a relatively new market, with the drug only being approved in 2017. It is a small but growing market, with Idhifa being the only drug approved for this indication. Some of the companies in the Idhifa market include Celgene Corporation, Agios Pharmaceuticals, and Daiichi Sankyo. Show Less Read more